Introduction
Vectors derived from herpes simplex virus (HSV) type 1 (HSV-1) have been shown to have broad potential for gene therapy of central nervous system (CNS) diseases, such as brain tumors or degenerative diseases. [1] [2] [3] The advantages of HSV-1 vector include: (1) the ability to infect a broad range of cells in both mitotic and nonmitotic phases; (2) the physical stability of the virus, allowing for on site application of high titers of virus; (3) the means of extensive genetic manipulation of the genome, so that at least 30 kb of the total 152 kb genome can be replaced by transgenes in some mutants. 4 HSV is a neurotropic virus and becomes latent in the nervous system after infection. 5, 6 Characteristically, latency-associated transcripts (LAT) are transcribed in neurons infected latently with HSV. 5, 7 Attenuated HSV expressing ␤-galactosidase (␤-gal) has been constructed by inserting the ␤-gal gene into the LAT region and then examined for its expression in the nervous system. 8, 9 However pathogenicity, such as neurovirulence, of a live replication-competent HSV vector [10] [11] [12] has lead to the development of a helper-dependent HSV vector to trans- fer the foreign genes into the neurons. [13] [14] [15] The helperdependent vector has little cytotoxic activity, but the number of copies introduced is limited to that of the inoculum when used as a vector. Nevertheless, a replication-competent virus can replicate in the broader area and increase the number of copies in the neurons, and lifelong expression of the foreign gene can be expected as long as the latent state continues as reviewed. 5 In contrast to laboratory rodents, which are not the natural host for HSV-1, 40-90% of all humans have antibodies against this human pathogen. 16, 17 The humoral and cellular immune response in immune hosts may be a possible obstacle for HSV-mediated gene transfer. Neutralizing antibodies might block the initial infection of target cells and the cellular immune response might lead to premature elimination of infected cells, thus reducing the number of transduced cells. 4 Evaluation of adenoviral gene transfer to liver, lung and muscle in rodents has revealed the immune-mediated elimination of cells expressing transgenes over weeks and markedly impaired gene delivery in cases of repeated vector application. [18] [19] [20] After injection to the brain, a relatively immunoprivileged site, the immune reaction against low amounts of adenovirus vectors and transgenes can be weak enough to allow transgene expression over months. 21, 22 Subsequent subcutaneous reinfection with adenovirus, however, can induce a systemic immune response which is strong enough to suppress adenovirus protein and transgene expression within the brain to undetectable levels and to induce autoimmune demyelination within 2 weeks. 23, 24 We have shown that intramuscular inoculation of live attenuated HSV vector, ␤H1, mediates transgene expression in a wide range of bilateral anterior horn motor neurons of the spinal cord for at least 182 days. 25 As the immunity to HSV may be a possible obstacle in this HSV gene delivery system, we have examined the effect of the pre-existing immunity to HSV on attenuated HSV-mediated gene delivery into the anterior horn motor neurons in this study. This vector has been applied in rats immunized subcutaneously and intramuscularly with the parent HSV strain before the application of a live HSV vector in the right gastrocnemius muscle. The present study is the first report to analyze the influence of HSV-1 immunization in setting of a live HSV-1 vector application to neuronal cells. The feasibility of this gene delivery system to anterior motor neurons of the spinal cord was confirmed in hosts immune, as well as non-immune to HSV.
Results

Antibody response to subcutaneous or intramuscular inoculation with the parent HSV
To address the feasibility of this gene delivery system in rats immune to HSV, two ways of immunization were performed in male Wistar rats (3-week-old) by subcutaneous or intramuscular inoculation with the parent HF strain. The HF strain with 1.0 × 10 7 plaque forming units (p.f.u.) was inoculated into rats subcutaneously in one group and into the right gastrocnemius muscle of rats in the other group. Subcutaneous or intramuscular immunization elicited a marked immune response to HSV, as determined by the increase in HSV-specific IgG antibody and serum titers of neutralizing antibodies. Immunized animals in two ways had significantly higher levels of IgG antibody by enzyme-linked immunosorbent assay (ELISA) up to day 28, and remained at high levels at the time of histological examination as shown in Figure 1a . Titers of neutralizing antibodies by 50% plaque reduction assay rose to a significantly higher level on day 7 in both immunized groups, and remained at that level up to the time of histological examination as shown in Figure 1b . Neither antibody titer was influenced by the inoculation of ␤H1, indicating the immune status to HSV was in the maximum status.
Gene delivery into the anterior horn motor neurons by attenuated HSV vector in non-immune and immune rats
Rats were first immunized subcutaneously with phosphate-buffered saline (PBS) or the HF strain, and 28 days later the ␤H1 strain was inoculated into their right gastrocnemius muscle. On day 28 after intramuscular inoculation with ␤H1, histological sections from the spinal cord were taken to examine the gene delivery into the anterior horn motor neurons. The cryostat sections were stained for ␤-gal activity. Histochemical analysis of these sections demonstrated that inoculation with ␤H1 in the right gastrocnemius muscle resulted in ␤-gal expression in the bilateral anterior horn motor neurons at the innervating lumbosacral level of the spinal cord in both subcutaneously immunized and non-immune animals. Figure 2 demonstrates that ␤-gal activity was localized in the bilateral anterior horn motor neurons in both subcutaneously immunized (Figure 2a ) and non-immune animals (Figure 2c ) at the L5 level of the spinal cord on day 28 after intramuscular inoculation with ␤H1. ␤-Gal expression was not observed in the sequential sections at the thoracic and lower sacral levels.
For histopathological analysis, sections were stained with hematoxylin and eosin. There were no apparent histopathological changes such as hemorrhagic necrosis, inflammatory infiltration, neuronophagia, patchy neuronal loss, gliosis or demyelination in the spinal cord of rats immunized subcutaneously as shown in Figure 3 .
Thirty-five days after inoculation with the parent HF strain into the right gastrocnemius muscle, ␤H1 was inoculated at the same site and histological analysis of the spinal cord was performed on 28 days later. ␤-Gal expression was observed in the bilateral anterior horn motor neurons at the innervating lumbosacral level of the spinal cord after inoculation with ␤H1 in the right gastro-
Figure 2 Expression of ␤-gal activity in the spinal cord (L5) on day 28 after inoculation of a live attenuated HSV-1 vector (␤H1). Expression of ␤-gal activity was observed in the bilateral anterior horn motor neurons in rats immunized subcutaneously (a), rats immunized intramuscularly (b), and non-immune rats (c).
There were no significant pathological changes caused by the inflammatory response in each group. The lower magnifications were × 20 and the higher magnifications were × 100.
cnemius muscle in spite of prior inoculation with the HF strain at the same site. Figure 2b shows the histology of the L5 level of the spinal cord on day 28 after inoculation with ␤H1 and ␤-gal activity was observed in the bilateral anterior horn motor neurons. This may be the second spread of HSV in the spinal cord, but there were no apparent histopathological changes such as hemorrhagic necrosis, inflammatory infiltration, neuronophagia, patchy neuronal loss, gliosis or demyelination in the spinal cord of rats immunized intramuscularly by hematoxylin-eosin staining (data not shown), similar to subcutaneous immunization.
Detection of ␤-gal mRNA by in situ hybridization
In situ hybridization for ␤-gal mRNA was performed in the histological sections from the spinal cord of the rat immunized subcutaneously on day 28 after intramuscular inoculation with ␤H1. A positive signal for ␤-gal mRNA was clearly detected in the cytoplasm of anterior horn motor neuron as shown in Figure 4 . Detection of ␤-gal mRNA in the anterior horn motor neurons was also consistent with ␤-gal activity in the serial sections stained with ␤-gal. Therefore, ␤-gal activity observed in the anterior horn motor neurons was due to the concurrent expression of the ␤-gal gene and not the remnant activity which was expressed in the acute phase of ␤H1 infection. Thus the demonstration of ␤-gal mRNA is clear evidence for the transgene expression in the anterior horn motor neurons on day 28 after intramuscular inoculation with ␤H1 in immune rats.
Effect of immunity on gene delivery in the anterior horn motor neurons
Apparent expression of ␤-gal activity within the anterior horn motor neurons was observed. Hence, the anterior horn motor neurons with ␤-gal activity were classified into three grades by the staining patterns: strong, weak, and negative staining. The distribution of ␤-gal activity in the subcutaneous immunization group is indicated in Figure 5 . The distribution of ␤-gal expression was no wider in subcutaneously immunized animals than in non-immune animals. Expression of ␤-gal was observed in about 50% of the anterior horn motor neurons in rats immunized subcutaneously as shown in Table 1 . However, about 85% of the anterior horn motor neurons expressed ␤-gal activity in non-immune animals on day 28 after intramuscular inoculation with ␤H1. Strong staining seemed to dominate in non-immune animals (about 15% in subcutaneously immunized animals; about 20% in non-immune animals), and the ratio of the strong staining in the positive neurons was statistically larger in Strongly positive cells and weakly positive cells indicate the two grades of positive cell as shown in Figure 3 . The percentage of ␤-gal expressing cells was determined by an average of one section per segment from L1 to S1 of all examined animals.
Gene Therapy non-immune animals than in immunized animals at the levels from L1 to S1, except for the L5 level by Student's t test (P Ͻ 0.05).
The distribution of ␤-gal activity in the intramuscular immunization group is indicated in Figure 5 . The distribution of ␤-gal expression was wider in animals inoculated secondarily using the same inoculation route of the right gastrocnemius, as compared with subcutaneously immunized animals. Expression of ␤-gal including strong and weak staining in three grades was observed in about 65% of the anterior horn motor neurons in secondarily inoculated animals as shown in Table 1 . Thus prior inoculation of HF strain might have facilitated the spread of ␤H1 infection and expression of ␤-gal in the anterior horn motor neurons.
Discussion
Our previous study has demonstrated that a live attenuated HSV vector (␤H1) successfully introduces ␤-gal activity into the anterior horn motor neurons of the spinal cord without apparent tissue destruction or inflammation in non-immune animals. 25 Expression of ␤-gal activity was recognized in 90% of the anterior horn motor neurons and lasted for over 182 days, even though this HSV vector had an attenuated nature. This gene expression occurred under the control of the LAT promoter during the latent phase of infection. Like HSV, known to become latent in the sensory ganglia, [26] [27] [28] [29] [30] this chimeric HSV-1 may enter the latent phase in the anterior horn motor neurons with expression of ␤-gal activity after transport from the skeletal muscle and interneuronal spread.
This study demonstrated that under conditions of preimmunization, a recombinant HSV-1 vector delivered transgene, such as ␤-gal, into neuronal cells in the rat spinal cord, but the extent of gene transfer was slightly attenuated under this condition. There was no apparent increase in neurotoxicity caused by the inflammatory response within the spinal cord associated with a preexisting anti-HSV-1 immune response. These findings support the potential utility of recombinant HSV-1 in the treatment of patients with CNS diseases that have antibodies to HSV-1.
Since rodents are not a natural host for HSV-1, rats do not have immunity to the virus, in contrast to most humans. To study the effectiveness and potential toxicity of HSV-1-mediated gene transfer under conditions of a pre-existing HSV-1 immunity, rats were immunized with the parent HF strain before intramuscular application of the vector. As an indicator of an anti-HSV immune reaction, high levels of HSV-specific IgG antibodies and neutralizing antibodies were demonstrated after subcutaneous or intramuscular immunization as shown in Figure  1a and b. HSV-1 vector was injected in the right gastrocnemius muscle in these animals at a time when the levels of IgG antibodies and neutralizing antibodies were at their peak in order to evaluate gene transfer in the 'worst case' scenario. These conditions may be suitable models for humans who have protective immunity induced with infections of wild-type HSV-1. 31 Our previous study 25 has demonstrated that ␤H1 continues to spread from 5 days after intramuscular inoculation with no spreading after 14 days and thereafter ␤H1 becomes latent in the anterior horn motor neurons. Subsequently, ␤-gal activity was predominantly observed in the bilateral anterior horn motor neurons for a prolonged period after inoculation with ␤H1. These findings suggest that the foreign gene can be expressed for a long time in the bilateral anterior horn motor neurons after intramuscular inoculation with ␤H1. Therefore in the present study, we evaluated gene delivery in the spinal cord by a live HSV-1 vector on day 28 after its intramuscular inoculation in immune rats.
On day 28 after intramuscular inoculation with ␤H1, ␤-gal activity was observed in the spinal cord at the level innervating the muscle in both animals immunized subcutaneously and non-immune animals. Neither inflammatory cells nor tissue destruction was observed in the spinal cord. Concerning the efficiency of gene delivery in the anterior horn motor neurons, the distribution of ␤-gal expression was not wider and the ratio of ␤-gal expressing cells was lower in animals immunized subcutaneously, as compared with non-immune animals as shown in Figure 5 and Table 1. HSV-1 immunization of animals did not block, but attenuated secondary virus infection of neuronal cells. Mester and Rouse 32 have reported that reduced efficiency of initial gene transfer to neuronal cells in immunized animals is probably mediated by neutralizing antibodies and HSV-1-specific cytotoxic T lymphocytes (CTL). Neutralizing antibodies are directed mainly against HSV-1 envelope glycoproteins. 33, 34 In contrast to neutralizing antibodies, CTL reacts not only against envelope glycoproteins, but also against immediate-early viral proteins, which are expressed early in infection even with nonreplicative HSV-1 mutants. [35] [36] [37] The present study demonstrated that there was also no apparent increase in neurotoxicity caused by the inflammatory response within the spinal cord in immunized animals, but the extent of gene transfer was slightly limited. The attenuated nature as reported previously 25 was preserved in immune rats, even in rats with repeated inoculation at the same site. Two strains of HSV-2 have been isolated from a patient and HSV-2 infects individuals who have immunity to HSV-1. 38, 39 Presence of immunity to HSV-1 usually attenuates the symptoms of HSV-2 infection compared with no immunity. Obara et al 40 have shown the coexistence of both HSV-1 and HSV-2 genomes in the wide range of dorsal root ganglia by PCR and in situ hybridization, and HSV-1 and HSV-2 infect and become latent in the same sensory ganglia. Our results are consistent with these observations in humans. Thus this finding may be one of the suitable characteristics of our vector system.
In the studies on the pre-existing immunity, the influence of the antiviral immune response on the spread of HSV infection was analyzed mainly in model systems using intratumoral application of replication-defective HSV-1 and mucocutaneous or intraocular application of wild-type virus. 4, 32, 41 The study of replication-defective HSV-1 application to experimental brain tumor demonstrated that pre-existing anti-HSV-1 immunity substantially decreased the extent of gene transfer, but did not completely abolish it. There was no apparent increase in neurotoxicity caused by the inflammatory response within the brain associated with a pre-existing anti-HSV-1 immune response. The present study is the first report to analyze the influence of HSV-1 immunization in the setting of a live HSV-1 vector application to neuronal cells.
Vectors derived from HSV-1 have been shown to have broad potential for gene therapy of CNS diseases. [1] [2] [3] Application of HSV-1 vector for the treatment of CNS diseases will require very prolonged expression of the recombinant gene. When further transgene expression is needed in the neurons, it is necessary to administer the recombinant virus expressing another gene in the same route. To evaluate gene delivery in repeated administration of HSV-1 vector, rats were inoculated with the HF strain into the right gastrocnemius muscle. Intramuscular immunization elicited a marked immune reaction as shown in Figure 1a and b. On day 28 after the first intramuscular inoculation, the sections from the spinal cord were immunostained for HSV antigen. No HSV-positive neuronal cells were seen (data not shown), indicating that HSV infected in the neurons latently.
On day 35 after the first administration of the parent HSV-1 virus, ␤H1 was injected into the same site. Twenty-eight days after the second intramuscular inoculation, ␤-gal expression was observed in the innervating lumbosacral level of the spinal cord without significant pathological changes. Regarding the efficiency of gene delivery in the anterior horn motor neurons, about 65% of them expressed ␤-gal activity in the wider range of the spinal cord in animals immunized intramuscularly, as compared with those immunized subcutaneously as shown in Figure 5 and Table 1 . Although the mechanism of facilitated gene delivery is not clear, this difference may be caused by the effect of latent HSV in the neurons delivered by the first inoculation of the patent HF strain.
In the studies with adenoviral vector, gene delivery in its repeated application has been hampered by the presence of immunity. In contrast, this study demonstrated that repeated administration of attenuated HSV-1 vector could efficiently deliver transgenes into neuronal cells in the rat spinal cord without neurotoxicity. These findings support the potential utility of recombinant HSV-1 mutants in treatment of patients with CNS disease that have necessity to repeat administration of the recombinant virus.
Genetic mutations in a number of inherited CNS diseases have been identified and these mutations indicate the possibility of gene therapy as one of many therapeutic approaches for these disorders. [42] [43] [44] [45] [46] [47] Replicationdefective adenovirus and replication-defective HSV-1 have both advantages and disadvantages as vectors for the gene therapy of CNS diseases. Our live HSV vector has little pathogenicity and in addition to the attenuated nature, the widespread and long-term expression of the foreign gene would be an advantage of this HSV vector. Furthermore, this live HSV vector can deliver transgenes into neuronal cells in the presence of immunity. Therefore this HSV vector system may be suitable as a gene delivery vector system for treatments of neurological diseases, especially affecting motor neurons.
Materials and methods
Preparation of a live attenuated HSV-1, ␤H1
A live attenuated HSV-1, ␤H1, was prepared as described previously. 48, 49 Briefly, ␤H1 was propagated in the Vero cell culture and harvested after three cycles of freezing and thawing of the culture. The culture medium was centrifuged at 3000 r.p.m. for 20 min at 4°C and the supernatant was stored at −85°C until use. The virus titer was determined with the overlay containing 5-bromo-4-chloro-3-indolyl-␤-d-galactoside (X-gal). No revertant virus was detected even in low dilution of the virus stock. The parent HF strain was prepared similarly.
Animals
Male Wistar rats (3-week-old; Japan SLC, Shizuoka, Japan) were used for subcutaneous and intramuscular immunization. Virus inoculation and behavioral experiments were done in the infection room (specific pathogen-free) of the Laboratory Animal Center (Toyama Medical and Pharmaceutical University). Procedures involving animals and their care were conducted conforming to the animal experimentation guidelines of Toyama Medical and Pharmaceutical University.
Immunization, determination of IgG antibody production by ELISA and assay for neutralizing anti-HSV antibody titer
For anti-HSV-1 immunization, rats were anaesthetized with Nembutal (50 mg/kg, intraperitoneal injection; Dainippon Pharmaceutical, Osaka, Japan). Animals were Gene Therapy then inoculated subcutaneously into the back or into the right gastrocnemius muscle with 1.0 × 10 7 p.f.u. of the HF strain per dose in 100 l without administration into the surrounding tissues such as blood vessels or nerves. Intramuscular inoculation was made using 1 ml syringe and a 26-gauge needle over a period of a few minutes and the syringe was left in place for an additional few minutes before withdrawal. As a control PBS was inoculated instead of the HF strain. For the determination of IgG antibody production and neutralizing antibody titers, blood samples from all animals were drawn from the tail vein of anesthetized animals before immunization and 7, 14, 21, 28 days after immunization, as well as at the time of histological analysis.
ELISA was performed as reported previously. 50 Briefly, ELISA plates were coated with HSV-1 (HF) antigen overnight at 4°C. The plates were washed with PBS and blocked with 3% skim milk in PBS. The optimum dilution of the first (rat serum) and second antibodies (peroxidaseconjugated rabbit anti-rat immunoglobulins; Dako Laboratories, Glostrup, Denmark) was determined by box titration. The reaction was visualized by OPD (Dako Laboratories). The combinations of antibody dilutions used were as follows: the rat serum and anti-rat IgG antibody were diluted 100-and 2000-fold, respectively, for IgG antibody determination. The antibody level was expressed as absorbance at 450 nm.
Neutralizing anti-HSV-1 antibody titers were determined using 50% plaque-reduction assay. Two-fold serial dilutions in medium were prepared from serum samples pooled from three animals per each group at each timepoint. Each serum dilution was mixed with 100 p.f.u. of HF strain, and incubated for 1 h at 37°C. Samples were inoculated to Vero cells in 60-mm plates and the residual HSV-1 infectivity was assayed. The plates were incubated at 37°C for 72 h, fixed with 5% neutral formalin, stained with 1% crystal violet, and the plaques were counted. The neutralizing antibody titer was defined as the highest serum dilution that reduced the number of plaques by 50% or more compared with negative controls.
Virus inoculation and histological analysis of the spinal cord of rats
After subcutaneous or intramuscular immunization, immune rats were anesthetized with Nembutal (50 mg/kg, intraperitoneal injection). Animals were then inoculated with 1.0 × 10 7 p.f.u. of ␤H1 per dose in 100 l into the right gastrocnemius muscle under direct inspection without administration into the surrounding tissues, such as blood vessels or nerves. Animals were anesthetized by ether, killed on day 28 after intramuscular inoculation, and perfused with cold PBS followed by 4% paraformaldehyde as reported previously. 25, 46 Tissues were removed and fixed in 4% paraformaldehyde for 1-4 h at 4°C. Tissues were cut smaller than 1 cm 3 and placed in 30% sucrose overnight. 51 Finally they were frozen in Tissue-Tek OCT embedding compound (Sakura Finetechnical, Tokyo, Japan). Fifty-m coronal sections of the spinal cord were cut on a Frigocut 2800N Cryostat (Finetec, Tokyo, Japan). The sections of the spinal cord were taken from thoracic 10 to sacral 3. The sections were reacted with X-gal 52 and then subsequently stained with neutral red.
To examine for histopathologic changes, tissues were removed, fixed with 4% paraformaldehyde in PBS at 4°C overnight, sequentially dehydrated with increasing concentrations of ethanol, embedded in paraffin, and cut into 4 m sections. The sections were stained with standard hematoxylin and eosin.
Preparation of probes
The ␤-galactosidase antisense oligo-DNAs selected were complementary to the mRNA sequence coding for nucleotides of ␤-gal gene 162-211 (5Ј-TCGCCATTCAGG CTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGC CTC-3Ј, nucleotides 222-271 (5Ј-TCGCACTCCAGCCAG CTTTCCGGCACCGCTTCTGGTGCCGGAAACCAGGC-3Ј), nucleotides 289-338 (5Ј-GATGGGCGCATCGTAA CCGTGCATCTGCCAGTTTGAGGGGACGACGACAG-3Ј). The oligo-DNAs were synthesized and labeled at their 5Ј-and 3Ј-end with biotin-16-dUTP by terminal deoxynucleotidyl transferase.
In situ hybridization
The procedures for pretreatments were described elsewhere. 53, 54 The frozen sections were fixed with 4% paraformaldehyde in PBS for 20 min at room temperature, treated with 0.2 n hydrochloric acid for 20 min at room temperature and digested with 1 g/ml of proteinase K for 15 min at 37°C. After post-fixation with 4% paraformaldehyde in PBS for 5 min, the sections were immersed in 2 mg/ml glycine in PBS twice for 15 min at room temperature, sequentially dehydrated with various concentrations of ethanol and dried.
Hybridization and detection of ␤-gal mRNA were accomplished using DNA probe hybridization/detection system in situ kit obtained from Maxim Biotech, Inc(San Francisco, CA, USA). Hybridization was carried out at 37°C overnight with the mixture of three different biotinoligo-DNA probes (0.3 g/ml, respectively) dissolved in the hybridization solution. After treatment with 15 g/ml RNase A at 37°C for 30 min and repeated washings, biotinylated probes were incubated with anti-biotin antibody at 37°C for 40 min followed by a immunoglobulin at 37°C for 20 min. To visualize the antibody/probe complex, streptavidin-alkaline phosphatase conjugate was applied and the signals were detected by the addition of BCIP/NBT solution.
Analysis
The expression of ␤-gal was observed using the Olympus AX80T (Olympus, Tokyo, Japan) microscope. The expression of ␤-gal activity was classified into three grades by the staining patterns: strong, weak and negative expression as indicated in Figure 5 . To improve accuracy, sections were examined by more than one individual.
